252 related articles for article (PubMed ID: 35130832)
21. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial.
Dodick DW; Lipton RB; Silberstein S; Goadsby PJ; Biondi D; Hirman J; Cady R; Smith J
Cephalalgia; 2019 Aug; 39(9):1075-1085. PubMed ID: 31234642
[TBL] [Abstract][Full Text] [Related]
22. Early clinical experience with eptinezumab: results of a retrospective observational study of patient response in the United States.
Starling AJ; Kymes S; Asher D; Soni-Brahmbhatt S; Karnik-Henry M
BMC Neurol; 2023 Apr; 23(1):158. PubMed ID: 37081405
[TBL] [Abstract][Full Text] [Related]
23. Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial.
Ashina M; Tepper SJ; Gendolla A; Sperling B; Ettrup A; Josiassen MK; Starling AJ
J Headache Pain; 2023 Nov; 24(1):155. PubMed ID: 37985968
[TBL] [Abstract][Full Text] [Related]
24. Long-term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication-overuse headache.
Blumenfeld A; Kudrow D; McAllister P; Boserup LP; Hirman J; Cady R
Headache; 2024 Jun; ():. PubMed ID: 38924044
[TBL] [Abstract][Full Text] [Related]
25. Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials.
Schim JD; Anderson C; Brunner E; Hirman J; Ogbru A; Cady R; McGill L
Headache; 2022 May; 62(5):558-565. PubMed ID: 35524405
[TBL] [Abstract][Full Text] [Related]
26. Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab.
Ayer DW; Skljarevski V; Ford JH; Nyhuis AW; Lipton RB; Aurora SK
Headache; 2018 Sep; 58(8):1225-1235. PubMed ID: 30106172
[TBL] [Abstract][Full Text] [Related]
27. Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II.
Dodick DW; Lipton RB; Ailani J; Halker Singh RB; Shewale AR; Zhao S; Trugman JM; Yu SY; Viswanathan HN
Headache; 2020 Apr; 60(4):686-700. PubMed ID: 32073660
[TBL] [Abstract][Full Text] [Related]
28. Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2.
Martin V; Nagy AJ; Janelidze M; Giorgadze G; Hirman J; Cady R; Mehta L; Buse DC
Clin Ther; 2022 Mar; 44(3):389-402. PubMed ID: 35131090
[TBL] [Abstract][Full Text] [Related]
29. Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies.
Pozo-Rosich P; Dodick DW; Ettrup A; Hirman J; Cady R
BMC Neurol; 2022 Oct; 22(1):394. PubMed ID: 36284281
[TBL] [Abstract][Full Text] [Related]
30. A real-world prospective observational study of eptinezumab in Asian patients with migraine.
Zhao YJ; Ong JJY; Sonu SK; Dang J; Ng CC; Herr KJ; Bose R; Jion YI
Headache; 2024 May; ():. PubMed ID: 38785386
[TBL] [Abstract][Full Text] [Related]
31. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1).
Ashina M; Saper J; Cady R; Schaeffler BA; Biondi DM; Hirman J; Pederson S; Allan B; Smith J
Cephalalgia; 2020 Mar; 40(3):241-254. PubMed ID: 32075406
[TBL] [Abstract][Full Text] [Related]
32. Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial.
Kudrow D; Cady RK; Allan B; Pederson SM; Hirman J; Mehta LR; Schaeffler BA
BMC Neurol; 2021 Mar; 21(1):126. PubMed ID: 33740902
[TBL] [Abstract][Full Text] [Related]
33. Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study.
Smith TR; Janelidze M; Chakhava G; Cady R; Hirman J; Allan B; Pederson S; Smith J; Schaeffler B
Clin Ther; 2020 Dec; 42(12):2254-2265.e3. PubMed ID: 33250209
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.
Lipton RB; Goadsby PJ; Smith J; Schaeffler BA; Biondi DM; Hirman J; Pederson S; Allan B; Cady R
Neurology; 2020 Mar; 94(13):e1365-e1377. PubMed ID: 32209650
[TBL] [Abstract][Full Text] [Related]
35. Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention.
Lipton RB; Goadsby PJ; Dodick DW; McGinley JS; Houts CR; Wirth RJ; Kymes S; Ettrup A; Østerberg O; Cady R; Ashina M; Buse DC
Headache; 2022 Jun; 62(6):690-699. PubMed ID: 35466430
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies.
Smith TR; Spierings ELH; Cady R; Hirman J; Ettrup A; Shen V
J Headache Pain; 2021 Nov; 22(1):143. PubMed ID: 34823467
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2.
Ashina M; McAllister P; Cady R; Hirman J; Ettrup A
Cephalalgia; 2022 Jul; 42(8):696-704. PubMed ID: 35302389
[TBL] [Abstract][Full Text] [Related]
38. Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials.
Smith TR; Spierings ELH; Cady R; Hirman J; Schaeffler B; Shen V; Sperling B; Brevig T; Josiassen MK; Brunner E; Honeywell L; Mehta L
J Headache Pain; 2021 Mar; 22(1):16. PubMed ID: 33781209
[TBL] [Abstract][Full Text] [Related]
39. Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine.
Pederson S; Biondi DM; Allan B; Cady R; Schaeffler B; Baker B; Latham J
Front Immunol; 2021; 12():765822. PubMed ID: 34759933
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of eptinezumab as preventive treatment for episodic/chronic migraine: A systematic review and meta-analysis.
Siahaan YMT; Hartoyo V; Hariyanto TI
Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1156-1168. PubMed ID: 35781694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
